General education only
Peptide therapy evidence and safety guide
Learn how clinicians think about evidence quality, safety, regulation and individual suitability. This page does not recommend, rank or advertise prescription-only treatments.
Suitability, access and safety depend on individual clinical context and Australian regulatory requirements. Speak with a registered practitioner for personal advice.
Evidence tiering
Different peptide-related claims sit at different evidence levels. A clinician distinguishes approved indications from emerging or unsupported claims.
Safety and suitability
History, current medicines, contraindications and monitoring requirements matter before any treatment discussion.
Regulatory-safe access
Avoid grey-market shortcuts. Public education should not be confused with a prescription pathway.
Reference library
Peptide topics by evidence category
These entries are educational references for clinician conversations. They are not product recommendations, condition matching, dosing advice or access instructions.
Growth Hormone Secretagogues
CJC-1295
GHRH agonist
Phase 2Script Required
Studies on CJC-1295 have shown promising results for increased HGH and muscle growth. Legal status in Australia: Script Required.
Ipamorelin
Ghrelin mimetic
Phase 2Script Required
Studies on Ipamorelin have shown promising results for growth hormone release and improved sleep. Legal status in Australia: Script Required.
GHRP-6
Ghrelin mimetic
Phase 2Script Required
GHRP-6 works through Ghrelin mimetic to support HGH release. Current research status: Phase 2.
Hexarelin
Ghrelin mimetic
Phase 2Script Required
Hexarelin is a growth hormone secretagogues peptide that has gained attention for its potential health benefits. Research suggests it may help with HGH release and cardioprotection.
BPC-157
GHRH agonist
Early ResearchApproved
Studies on BPC-157 have shown promising results for therapeutic applications. Legal status in Australia: Research Only.
Modified Epithalon-acetate
GHRH agonist
Phase 2Approved
Modified Epithalon-acetate works through specific mechanisms to support health goals. Current research status: Under investigation.
Pegylated BPC-157
GHRH agonist
ApprovedScript Required
Pegylated BPC-157 works through specific mechanisms to support health goals. Current research status: Under investigation.
Epithalon(modified)
GHRH agonist
Phase 1Research Only
Epithalon(modified) works through specific mechanisms to support health goals. Current research status: Under investigation.
Tissue Repair
BPC-157
Collagen synthesis
PreclinicalResearch Only
BPC-157 works through Collagen synthesis to support wound healing. Current research status: Preclinical.
TB-500
Angiogenesis
PreclinicalResearch Only
TB-500 works through Angiogenesis to support tissue repair. Current research status: Preclinical.
Acetylated Semaglutide
GHRH agonist
Early ResearchApproved
Acetylated Semaglutide works through specific mechanisms to support health goals. Current research status: Under investigation.
Hexarelin
GHRH agonist
ApprovedResearch Only
Hexarelin works through specific mechanisms to support health goals. Current research status: Under investigation.
CJC-1295
GHRH agonist
Phase 1Script Required
CJC-1295 works through specific mechanisms to support health goals. Current research status: Under investigation.
TB-500
GHRH agonist
Phase 1Approved
Studies on TB-500 have shown promising results for therapeutic applications. Legal status in Australia: Research Only.
MOTS-c
GHRH agonist
PreclinicalResearch Only
MOTS-c is a metabolic regulation peptide that has gained attention for its potential health benefits. Research suggests it may help with various health outcomes.
Acetylated GHRP-6
GHRH agonist
Phase 1Research Only
Acetylated GHRP-6 works through specific mechanisms to support health goals. Current research status: Under investigation.
Metabolic Regulation
Semaglutide
GLP-1 agonist
ApprovedApproved (Ozempic)
Semaglutide works through GLP-1 agonist to support weight loss. Current research status: Approved.
MOTS-c
Mitochondrial regulation
Early ResearchResearch Only
MOTS-c is a metabolic regulation peptide that has gained attention for its potential health benefits. Research suggests it may help with metabolic health and longevity.
Selank
GHRH agonist
PreclinicalApproved
Selank is a cognitive enhancement peptide that has gained attention for its potential health benefits. Research suggests it may help with various health outcomes.
Ipamorelin
GHRH agonist
Early ResearchResearch Only
Ipamorelin is a growth hormone secretagogues peptide that has gained attention for its potential health benefits. Research suggests it may help with various health outcomes.
BPC-157
GHRH agonist
ApprovedApproved
BPC-157 works through specific mechanisms to support health goals. Current research status: Under investigation.
Epithalon
GHRH agonist
Early ResearchResearch Only
Epithalon is a cognitive enhancement peptide that has gained attention for its potential health benefits. Research suggests it may help with various health outcomes.
PEG- Semaglutide
GHRH agonist
PreclinicalScript Required
Studies on PEG- Semaglutide have shown promising results for therapeutic applications. Legal status in Australia: Research Only.
Hexarelin
GHRH agonist
Phase 2Research Only
Hexarelin works through specific mechanisms to support health goals. Current research status: Under investigation.
Cognitive Enhancement
Epithalon
Telomerase activation
PreclinicalResearch Only
Epithalon is a cognitive enhancement peptide that has gained attention for its potential health benefits. Research suggests it may help with longevity and anti-aging.
Selank
Neuroprotection
Phase 2Research Only
Selank is a cognitive enhancement peptide that has gained attention for its potential health benefits. Research suggests it may help with anxiety reduction and cognitive enhancement.
Ipamorelin
GHRH agonist
ApprovedResearch Only
Studies on Ipamorelin have shown promising results for therapeutic applications. Legal status in Australia: Research Only.
MOTS-c
GHRH agonist
Phase 2Approved
MOTS-c works through specific mechanisms to support health goals. Current research status: Under investigation.
Selank-amide
GHRH agonist
ApprovedResearch Only
Selank-amide is a cognitive enhancement peptide that has gained attention for its potential health benefits. Research suggests it may help with various health outcomes.
Epithalon
GHRH agonist
PreclinicalScript Required
Epithalon is a cognitive enhancement peptide that has gained attention for its potential health benefits. Research suggests it may help with various health outcomes.
BPC-157
GHRH agonist
Early ResearchScript Required
Studies on BPC-157 have shown promising results for therapeutic applications. Legal status in Australia: Research Only.
MOTS-c
GHRH agonist
ApprovedResearch Only
Studies on MOTS-c have shown promising results for therapeutic applications. Legal status in Australia: Research Only.
Sarcopenia Treatment
CJC-1295-acetate
GHRH agonist
Phase 1Script Required
CJC-1295-acetate is a growth hormone secretagogues peptide that has gained attention for its potential health benefits. Research suggests it may help with various health outcomes.
Pegylated TB-500
GHRH agonist
Phase 1Script Required
Studies on Pegylated TB-500 have shown promising results for therapeutic applications. Legal status in Australia: Research Only.
GHRP-6
GHRH agonist
Phase 2Script Required
GHRP-6 works through specific mechanisms to support health goals. Current research status: Under investigation.
Ipamorelin
GHRH agonist
Phase 2Research Only
Ipamorelin works through specific mechanisms to support health goals. Current research status: Under investigation.
Semaglutide
GHRH agonist
PreclinicalScript Required
Semaglutide works through specific mechanisms to support health goals. Current research status: Under investigation.
Acetylated Hexarelin
GHRH agonist
Early ResearchScript Required
Acetylated Hexarelin is a growth hormone secretagogues peptide that has gained attention for its potential health benefits. Research suggests it may help with various health outcomes.
PEG- TB-500
GHRH agonist
Phase 1Research Only
PEG- TB-500 works through specific mechanisms to support health goals. Current research status: Under investigation.
Pegylated Semaglutide
GHRH agonist
Phase 2Approved
Studies on Pegylated Semaglutide have shown promising results for therapeutic applications. Legal status in Australia: Research Only.
Use education as a clinician conversation starter.
If you are considering care, start with suitability and clinical review rather than trying to self-select a therapy from internet claims.
Start eligibility review